Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Oct 12, 2024. (Total: 232444Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 10 (of 10 Records)

Query Trace: Lung Neoplasms and CYP2C19[original query]
Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population.
World journal of gastroenterology : WJG 2004 Jul 10 (13): 1961-3.
Shi Wei-Xing, Chen Shu-Qi
CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.
Acta oncologica (Stockholm, Sweden) 2007 46 (3): 361-6.
Pan Ji-Hong, Han Jin-Xiang, Wu Jian-Mei, Sheng Li-Jun, Huang Hai-N
Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers.
European journal of clinical pharmacology 2012 Dec 68 (12): 1677-80.
Ruan Can-Jun, Liu Dong-Yang, Jiang Ji, Hu P
Poor metabolizers at the cytochrome P450 2C19 loci is at increased risk of developing cancer in Asian populations.
PloS one 2013 8 (8): e73126.
Wang Hong, Song Kang, Chen Zenggan, Yu Yanm
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Jun 24 (6): 1653-9.
Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
British journal of cancer 2013 Nov 109 (11): 2803-9.
Yamamoto N, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Asian Pacific journal of cancer prevention : APJCP 2014 15 (17): 7195-200.
Chen Jia, Zheng Xin, Liu Dong-Yang, Zhao Qian, Wu Yi-Wen, Tan Fen-Lai, Wang Yin-Xiang, Jiang Ji, Hu P
Interaction between smoking and CYP2C19*3 polymorphism increased risk of lung cancer in a Chinese population.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014 Jun 35 (6): 5295-8.
Yan Fei, Xu Jin-Fu, Liu Xiao-fang, Li Xing-H
Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.
European journal of clinical pharmacology 2015 Jul 71 (7): 843-50.
Hu Pei, Chen Jia, Liu Dongyang, Zheng Xin, Zhao Qian, Jiang
Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer.
Frontiers in pharmacology 2022 13 918219.
Tan Tingfei, Han Gongwei, Cheng Ziwei, Jiang Jiemei, Zhang Li, Xia Zitong, Wang Xinmeng, Xia Qu
TOP